Mlh1 Deficiency Increases the Risk of Hematopoietic Malignancy After Simulated Space Radiation Exposure
Overview
Authors
Affiliations
Cancer-causing genome instability is a major concern during space travel due to exposure of astronauts to potent sources of high-linear energy transfer (LET) ionizing radiation. Hematopoietic stem cells (HSCs) are particularly susceptible to genotoxic stress, and accumulation of damage can lead to HSC dysfunction and oncogenesis. Our group recently demonstrated that aging human HSCs accumulate microsatellite instability coincident with loss of MLH1, a DNA Mismatch Repair (MMR) protein, which could reasonably predispose to radiation-induced HSC malignancies. Therefore, in an effort to reduce risk uncertainty for cancer development during deep space travel, we employed an Mlh1 mouse model to study the effects high-LET Fe ion space-like radiation. Irradiated Mlh1 mice showed a significantly higher incidence of lymphomagenesis with Fe ions compared to γ-rays and unirradiated mice, and malignancy correlated with increased MSI in the tumors. In addition, whole-exome sequencing analysis revealed high SNVs and INDELs in lymphomas being driven by loss of Mlh1 and frequently mutated genes had a strong correlation with human leukemias. Therefore, the data suggest that age-related MMR deficiencies could lead to HSC malignancies after space radiation, and that countermeasure strategies will be required to adequately protect the astronaut population on the journey to Mars.
Finkelstein S, Patel R, Deland K, Mercer J, Starr B, Zhu D Radiat Res. 2024; 202(5):734-744.
PMID: 39307527 PMC: 11608577. DOI: 10.1667/RADE-24-00004.1.
Sun M, Moquet J, Ellender M, Bouffler S, Badie C, Baldwin-Cleland R Fam Cancer. 2022; 22(1):61-70.
PMID: 35718836 PMC: 9829596. DOI: 10.1007/s10689-022-00299-9.
DNA damage and repair in the hematopoietic system.
Li N, Chen H, Wang J Acta Biochim Biophys Sin (Shanghai). 2022; 54(6):847-857.
PMID: 35593466 PMC: 9909303. DOI: 10.3724/abbs.2022053.
Lee C, Brock K, Hasapis S, Zhang D, Sibley A, Qin X Cancer Res. 2021; 81(14):3777-3790.
PMID: 34035082 PMC: 8286346. DOI: 10.1158/0008-5472.CAN-20-2823.
Devall M, Casey G Oncotarget. 2021; 12(8):767-782.
PMID: 33889300 PMC: 8057268. DOI: 10.18632/oncotarget.27935.